| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b8e71233d46c313ac971fc4f9e4aa4d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 |
| filingDate |
2018-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd18beb2d58098a2d31bcda7f7dd6d18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16c8a5b230c1248095b84a6edb64adc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8f2725682d661e58f706188c81b5ce8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d28d170be6e9e12520d6efb7d0e8e63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_758059decf22dc49143050ed458b47a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c416c53fa851b21a0bb7ab24159e8a4f |
| publicationDate |
2019-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190122739-A |
| titleOfInvention |
Cysteine Modified Antibodies for Conjugation |
| abstract |
The present invention provides a modified heavy chain constant region comprising cysteine at EU numbering position 295 and optionally, at EU numbering position 239. These cysteine residues provide a site for conjugation to the drug or label. If both cysteines are present in the normal heterodimer antibody format, there are four such sites per antibody molecule, which allows for stoichiometry of one molecule of antibody to four drugs or labels. The choice of cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity. |
| priorityDate |
2017-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |